Form 4: Silence Therapeutics Director, James Ede-Golightly, Acquires Share Options

Director James Ede-Golightly acquired share options in Silence Therapeutics plc on January 2, 2025.

Summary

• James Ede-Golightly, a director of Silence Therapeutics plc, acquired 48,000 share options on January 2, 2025.
• The exercise price of these options is $2.4.
• The options vest in equal monthly installments over three years, starting one month after January 2, 2025, contingent upon continuous service.
• The options expire on January 2, 2035.
• Following the transaction, Ede-Golightly directly owns 48,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of share options by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• A director's acquisition of share options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the director, aligning his interests with the company's performance over the next three years.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of share options by a director can positively influence shareholder sentiment.

Key Dates